On the other hand, decreased expression of IGFBP-3 was observed in liver hepatocellular carcinoma (log2 fold change −2.53), kidney chromophobe (log2 fold change −1.07), breast invasive carcinoma (log2 fold change −0.82), prostate adenocarcinoma (log2 fold change −0.56), and uterine corpus endometrial carcinoma (log2 fold change −0.43). Here, IGFBP3 is linked to prostate adenocarcinoma.